Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000288923 refers to a novel, non-coding RNA transcript annotated as "sense intronic to NLK," meaning it is transcribed from the same genomic strand as the NLK gene and lies within an NLK intron. There is no evidence this transcript encodes a protein, nor that it functions as a therapeutic target, molecular marker, or biomarker. No biological function or disease association has been established for this transcript, and it is not considered a target for pharmacological intervention. Such entries are commonly cataloged due to high-throughput transcriptomic projects but often lack functional characterization[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, sense intronic to NLK (ENSG00000288923).